AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31887090
Drug: AB‐dex (alfaxalone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB‐dex (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with dexmedetomidine [0.005 mg/kg])
Trial: 31438618
Drug: Rifaximin for
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin for 10 days followed by nutraceutical agent (G1)
Trial: 25222572
Drug: Fish aquarium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish aquarium animal‐assisted therapy (FA‐AAT)
Trial: 21102369
Drug: Topical tetracaine
RxNorm normalized name: tetracaine Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracaine
Trial: 15085492
Drug: Poractant alfa
RxNorm normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Poractant alfa (Curosurf) 100 mg/kg
Trial: 15085492
Drug: Poractant alfa
RxNorm normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Poractant alfa (Curosurf) 200 mg/kg
Trial: 15085492
Drug: Beractant (Survanta)
RxNorm normalized name: Beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beractant (Survanta) 100 mg/kg
Trial: 11420324
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg ketamine
Trial: 10322818
Drug: IKPA tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IKPA tablets and inhalated BDP
Trial: 29773516
Drug: Lymphoedema management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoedema management package including instructions for foot hygiene, skin care, bandaging, exercises, and use of socks and shoes, supported by lay Community Podoconiosis Agents at monthly meetings.
Trial: 27073044
Drug: Topical liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical liposomal azithromycin administered twice daily
Trial: 27073044
Drug: Intralesional meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional meglumine antimoniate (glucantime) administered weekly with a volume of 0.5-2 cm3 into each lesion
Trial: 22342850
Drug: Dual-antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet therapy with aspirin and clopidogrel
Trial: 22342850
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with OAC, aspirin, and clopidogrel
Trial: 29447773
Drug: OAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC plus aspirin
Trial: 22342850
Drug: OAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC with either 1 or 2 antiplatelet agents
Trial: 15290154
Drug: Anecortave Acetate
RxNorm normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anecortave Acetate for Depot Suspension (3, 15 and 30 mg)
Trial: 7492378
Drug: Surgery for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery for cure followed by postoperative chemotherapy (CAV - cyclophosphamide, doxorubicin, vincristine)
Trial: 2182696
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg sustained-release theophylline (morning and evening)
Trial: 2182696
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg sustained-release theophylline (two capsules morning and evening)
Trial: 2182696
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules morning and evening)
Trial: 1096539
Drug: Unilateral ECT
RxNorm normalized name: ECT-001 expanded cord blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral ECT treatment
Trial: 1096539
Drug: Bilateral ECT
RxNorm normalized name: ECT-001 expanded cord blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ECT treatment
Trial: 15126259
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (CT)
Trial: 22338468
Drug: Procalcitonin-guided antibiotic
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin-guided antibiotic treatment (PCT-group; n = 102)
Trial: 16682147
Drug: Androgen suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen suppression therapy (AST) administered at a PSA level of approximately 10 ng/mL
Trial: 14745141
Drug: Intravenous atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous atrial natriuretic peptide (ANP) administration
Trial: 7962387
Drug: Method C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method C: no further treatment with the Percoll gradient
Trial: 3297471
Drug: Insulin (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.15 unit/kg body weight)
Trial: 23676766
Drug: 0.1 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 µg rESAT6
Trial: 23676766
Drug: 0.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 µg rESAT6
Trial: 23676766
Drug: 1 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg rESAT6
Trial: 20951320
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitor administration in poor responders
Trial: 20951320
Drug: Poor response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Poor response to aspirin
Trial: 16945048
Drug: Heparin flushes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin flushes (3 ml of porcine heparin 100 U/ml, 300 U per catheter lumen at least once/day)
Trial: 16945048
Drug: Lepirudin flushes
RxNorm normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lepirudin flushes (3 ml of lepirudin 100 microg/ml, 300 microg per catheter lumen at least once/day)
Trial: 11315234
Drug: Tiludronate 50
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronate 50 mg/day
Trial: 8216439
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) spray preparation (Isoket Spray) 2.5 mg per valve release
Trial: 8216439
Drug: Reference spray
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference spray preparation
Trial: 8216439
Drug: Isosorbide-2-mononitrate (IS-2-MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-2-mononitrate (IS-2-MN) from test spray
Trial: 8216439
Drug: Isosorbide-2-mononitrate (IS-2-MN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-2-mononitrate (IS-2-MN) from reference spray
Trial: 8216439
Drug: Isosorbide-5-mononitrate (IS-5-MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5-MN) from test spray
Trial: 8216439
Drug: Isosorbide-5-mononitrate (IS-5-MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5-MN) from reference spray
Trial: 2890019
Drug: Post-treatment Campylobacter
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment Campylobacter pylori status
Trial: 28380313
Drug: Cholesterol-lowering medication
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering medication (CLM) during endocrine therapy
Trial: 21209140
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist service (medication reviews, feedback to physicians, drug treatment discussions, medication reports)
Trial: 19128534
Drug: Cognitive-motor dual-tasking
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-motor dual-tasking training program (5 weeks, twice-daily practice)
Trial: 25542604
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser treatment
Trial: 2905808
Drug: Lormetazepam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (0.02 mg/kg) followed by Ro 15‐1788 (0.03 mg/kg)
Trial: 2905808
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (0.03 mg/kg) alone
Trial: 2905808
Drug: Lormetazepam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (0.02 mg/kg)
Trial: 2905808
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (0.03 mg/kg)
Trial: 2905808
Drug: Lormetazepam group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam group prior to administration
Trial: 30193927
Drug: LE gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LE gel 2 times a day
Trial: 30193927
Drug: LE gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LE gel 3 times a day
Trial: 27349272
Drug: Intrathecal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal dexmedetomidine (5 µg)
Trial: 27349272
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (100 µg)
Trial: 22537244
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of chocolate (70% cocoa) daily (Group A)
Trial: 19915454
Drug: Quetiapine 50
RxNorm normalized name: quetiapine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 50 mg every 12 hrs, increased as needed up to 200 mg every 12 hrs
Trial: 10947303
Drug: Thymoglobulin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (1.5 mg/kg/day for an average of 10 days)
Trial: 10947303
Drug: Atgam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atgam (15 mg/kg/day for an average of 9.7 days)
Trial: 2004962
Drug: Simulated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated with oral contrast
Trial: 2004962
Drug: Simulated without
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated without oral contrast
Trial: 30935524
Drug: Melatonin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (high dose [24 mg], sustained-release formulation)
Trial: 29454227
Drug: l-Carnitine 2g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-Carnitine 2g/day for one week
Trial: 25070319
Drug: Metreleptin (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.06 to 0.24 mg/kg/d) for 6 months to 11 years
Trial: 23278572
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg EN101
Trial: 23278572
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg EN101
Trial: 23278572
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg EN101
Trial: 8732611
Drug: Intravenous thiopentone
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thiopentone (group I)
Trial: 8732611
Drug: Halothane inhalation
RxNorm normalized name: Halothane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halothane inhalation (group II)
Trial: 8732611
Drug: Rectal methohexitone
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal methohexitone (group III)
Trial: 6214438
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg desogestrel + 0.050 mg ethinylestradiol
Trial: 6214438
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol
Trial: 31357887
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination
Trial: 17962426
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination
Trial: 24692082
Drug: Neoadjuvant letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant letrozole (LET) administered for 24-28 weeks before surgery
Trial: 17471547
Drug: Creatine supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplements (20 gm/day for 8 days, then 3 gm/day)
Trial: 17471547
Drug: Creatine supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplements
Trial: 10822073
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and aspirin (group 1)
Trial: 10822073
Drug: Argatroban and
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban and aspirin (group 2)
Trial: 1639946
Drug: Exogenous melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous melatonin (2.5 mg, orally) during the daytime (n = 6)
Trial: 1639946
Drug: Suppression of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppression of endogenous nocturnal melatonin secretion by atenolol (100 mg; n = 6)
Trial: 1639946
Drug: Daytime melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daytime melatonin administration
Trial: 6712031
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose recombinant alpha-2 interferon (50 X 10(6) U/m2 body surface area, intravenously)
Trial: 6712031
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose recombinant alpha-2 interferon (1 X 10(6) U/m2, subcutaneously)
Trial: 6712031
Drug: Both high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high and low doses of recombinant alpha-2 interferon
Trial: 31741230
Drug: Biomarker-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided therapy
Trial: 24476536
Drug: Intrauterine injection
RxNorm normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine injection of 500 IU of human chorionic gonadotropin (hCG) before embryo transfer
Trial: 24476536
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hCG injection)
Trial: 20665209
Drug: Oxycodone (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (5, 10, and 20 mg/10 ml)
Trial: 20665209
Drug: Hydrocodone (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone (5, 10, and 20 mg/10 ml)
Trial: 20665209
Drug: Morphine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5, 10, and 20 mg/10 ml)
Trial: 9704792
Drug: Antiphospholipid antibody
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiphospholipid antibody
Trial: 8580691
Drug: More concentrated
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More concentrated PAP (10 ml = 15 grams of Astragalus)
Trial: 8580691
Drug: Less concentrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less concentrated PAP (10 ml = 5 grams of Astragalus)
Trial: 31192359
Drug: Supervised machine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised machine learning approach using PBP sequences and MIC values to predict antimicrobial susceptibility to beta-lactam antibiotics.
Trial: 28251282
Drug: S-1 alternate-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 alternate-day treatment (twice daily on alternate days from days 1 through 42 of a 42-day cycle)
Trial: 28251282
Drug: S-1 daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 daily treatment (twice daily on days 1 through 28 of a 42-day cycle)
Trial: 28251282
Drug: S-1 alternate-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 alternate-day treatment
Trial: 28251282
Drug: S-1 daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 daily treatment
Trial: 18710817
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (NGF) injection in trapezius muscle
Trial: 18710817
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection in trapezius muscle (control)
Trial: 16752180
Drug: [U‐(13)C]glucose and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [U‐(13)C]glucose and [3‐(14)C]lactate infusion during a 24‐h fast
Trial: 15177970
Drug: One 600‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 600‐mg tablet (group 1A, 13 patients sampled < 2 hours after administration)
Trial: 15177970
Drug: One 600‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 600‐mg tablet (group 1B, 9 patients sampled > 2 hours after administration)
Trial: 15177970
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 600 mg given 12 hours apart (group 2, 7 patients)
Trial: 3112262
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.1 mg/kg)
Trial: 24225450
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg daidzein (DAI40)
Trial: 24225450
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg daidzein (DAI80)
Trial: 20937093
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (25,000 U) administered 4 or 6 hourly depending on patient height
Trial: 20937093
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) administered 4 or 6 hourly depending on patient height
Trial: 18763689
Drug: Oral‐B P40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B P40 manual toothbrush (MTB)
Trial: 16105056
Drug: Cinacalcet (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30 to 180 mg once daily)
Trial: 31478731
Drug: Multi-drug resistance
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug resistance
Trial: 26115954
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for depression, 8 weeks
Trial: 22916864
Drug: Titanium-polyethylene (TI)
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium-polyethylene (TI) implant
Trial: 22916864
Drug: Pyrocarbon (PY)
RxNorm normalized name: PARAFFIN HYDROCARBONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrocarbon (PY) implant
Trial: 20581660
Drug: Dexamethasone (HD-DXM)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (HD-DXM) at single daily doses of 40 mg for 4 consecutive days
Trial: 17295794
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (daily for the first 6 months of life)
Trial: 17295794
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for the first 6 months of life)
Trial: 2036815
Drug: Aerosol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol therapy
Trial: 2036815
Drug: Humidity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidity therapy
Trial: 7094200
Drug: Chemotherapy (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (with or without radiotherapy) plus MER/BCG (RCM)
Trial: 7094200
Drug: Chemotherapy either
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy either alone or in combination with radiotherapy (RC)
Trial: 26947543
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (IVTXA)
Trial: 26947543
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (TTXA)
Trial: 14711141
Drug: Topical 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5‐FU
Trial: 14711141
Drug: PDT treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT treatments (both types)
Trial: 11281438
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg tid + Omeprazole 20 mg bd
Trial: 11281438
Drug: Amoxycillin 750
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 750 mg tds + Omeprazole 20 mg bd